Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $28.5100 (5.91%) ($27.2500 - $29.1550) on Wed. Nov. 4, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.65% (three month average) | RSI | 40 | Latest Price | $28.5100(5.91%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2% a day on average for past five trading days. | Weekly Trend | TGTX declines -4.1% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Rotation from value to growth for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -1.825% in a week (0% probabilities). VIXM(-37%) VXX(-34%) UUP(-19%) IGOV(-3%) TBT(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.825% (StdDev 3.65%) | Hourly BBV | 1.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $26.62(7.1%) | 10 Day Moving Average | $26.58(7.26%) | 20 Day Moving Average | $28.08(1.53%) | To recent high | -8.4% | To recent low | 54.2% | Market Cap | $3.611b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |